載入中
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
前收盤價
US$4.69
−US$0.21 · -4.29%
盤後
US$4.80
+US$0.11 · +2.35%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
日內區間
目前US$4.69
52週區間
目前US$4.69
盤中時間採用ET。市場資料可能有所延遲。
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
日內區間
目前US$4.69
52週區間
目前US$4.69
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|
| 銷貨成本 | 64.7萬 USD | 66.8萬 USD | — | — |
| 毛利 | −64.7萬 USD | −66.8萬 USD | — | — |
| 研究與開發 | 6026.3萬 USD | 5728.8萬 USD | 4062.6萬 USD | 3460.5萬 USD |
| 銷售、一般及管理費用 | 2871.9萬 USD | 1326.8萬 USD | 970.7萬 USD | 676.7萬 USD |
| 營業費用 | 8833.5萬 USD | 6988.8萬 USD | 5033.3萬 USD | 4137.2萬 USD |
| 利息收入 | 1329.5萬 USD | 817萬 USD | 276.9萬 USD | 113.2萬 USD |
| 折舊和攤銷 | 64.7萬 USD | 66.8萬 USD | 58.3萬 USD | 12.2萬 USD |
| 營業利益 | −8898.2萬 USD | −7055.6萬 USD | −5033.3萬 USD | −4137.2萬 USD |
| 淨利 | −7526.8萬 USD | −6168.8萬 USD | −4726.3萬 USD | −4024萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$27.40
上漲空間 484.22%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI563.59萬0.00%2.3兆 USD0.03%US$381.57-0.10%
Vanguard U.S. Momentum Factor ETFVFMO242.2萬0.12%19億 USD0.13%US$227.71-1.04%
iShares Russell 2000 ETFIWM240.37萬0.00%787.4億 USD0.19%US$277.9-0.37%
iShares Biotechnology ETFIBB101.08萬0.01%108.2億 USD0.44%US$204.26-1.08%
Vanguard Extended Market ETFVXF100.9萬0.00%954億 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO84.53萬0.01%139.17億 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO63.8萬0.00%180億 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA49.71萬0.00%218.24億 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIVanguard U.S. Momentum Factor ETFVFMOiShares Russell 2000 ETFIWMiShares Biotechnology ETFIBBVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
